This press release contains forward-looking statements, including, without limitation, statements related to: the presentation of data from STELLAR-001 during the Poster Session at the 2022 ESMO Congress; the therapeutic potential of XL092, both alone and in combination with immune checkpoint inhibitors, as a therapy for cancer patients in need of new treatment options; and Exelixis' plans to reinvest in its business to maximize the potential of the company's pipeline, including through targeted business development activities and internal drug discovery.